Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean ultrices consectetur eleifend. Nulla tincidunt sapien non est ornare, quis tincidunt eros porttitor.
The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.
Lorem ipsum dolor sit amet. Et explicabo aliquam ut aliquid minus ut quasi necessitatibus ex corporis minima At omnis Quis eos commodi illum et velit nobis. Ut molestiae iste sed iste unde est dolores suscipit sit necessitatibus facilis et alias libero!
Type 1 diabetes, non-alchoholic steatohepatitis, pulmonary inflammation
Through an agreement, Adhera has exclusive worldwide rights to develop MLR-1023 for Type 1 diabetes, Non-Alcoholic Steatohepatitis, Pulmonary Inflammation. Adhera will utilize extensive clinical data on MLR-1023 to move directly into Phase 2 clinical trials for these indications.
Type 1 diabetes, non-alchoholic steatohepatitis, pulmonary inflammation
The company’s ‘next-generation of celecoxib,’ including IT-102 and IT-103, are designed to control the dangerous side-effect of edema that prohibits the drug from being prescribed at higher doses. These have the potential of replacing opioids and combatting the opioid epidemic.
